Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin

J Clin Invest. 1987 Feb;79(2):468-72. doi: 10.1172/JCI112835.

Abstract

The effect of intravenous gammaglobulin (IVGG) on the immunoregulatory abnormalities found during acute Kawasaki syndrome (KS) was studied in a randomized trial of IVGG plus aspirin (ASA) versus ASA alone. Before therapy, patients in each treatment group had increased numbers of circulating HLA-DR-bearing Leu 3+ helper T cells, a deficiency of Leu 2+ suppressor/cytotoxic T cells, and increased levels of spontaneous IgG and IgM synthesis by peripheral blood mononuclear cells. There were no significant differences (P greater than 0.1) between immunologic parameters measured on day 1 and day 4 in the ASA-treated group. In contrast, patients treated with ASA plus IVGG had by day 4 a highly significant decrease in HLA-Dr+ Leu 3+ helper T cells (P less than 0.001), an increase in Leu 2+ suppressor/cytotoxic T cells (P less than 0.01), and a decrease in spontaneous IgG (P less than 0.01) and IgM synthesis (P less than 0.001). These changes were associated with a reduction in the secretion of T cell-derived B cell helper factors (P less than 0.001). These findings indicate that treatment with IVGG suppresses the marked T and B cell activation found in patients with acute KS.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Monoclonal
  • Aspirin / therapeutic use*
  • Child, Preschool
  • Clinical Trials as Topic
  • Female
  • HLA-DR Antigens / analysis
  • Humans
  • Infusions, Intravenous
  • Lymphocyte Activation*
  • Male
  • Mucocutaneous Lymph Node Syndrome / immunology*
  • Mucocutaneous Lymph Node Syndrome / therapy
  • Random Allocation
  • Reference Values
  • T-Lymphocytes / classification
  • T-Lymphocytes / immunology
  • gamma-Globulins / administration & dosage
  • gamma-Globulins / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • HLA-DR Antigens
  • gamma-Globulins
  • Aspirin